 |
22 Diseases |  |
0 Trials |
|
0 Trials |  |
180 News |  |
| «123» |
- ||| oprozomib (ONX 0912) / Amgen
Oprozomib Found Active in Multiple Myeloma, Waldenström Macroglobulinemia - Cancer Therapy Advisor https://t.co/Y9d3gM3b9J @CancerTherAdvsr (Twitter) - Jul 30, 2019
- | oprozomib (ONX 0912) / Amgen
Trial completion, Metastases: A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies (clinicaltrials.gov) - Jul 18, 2019
P1, N=43, Completed, Sponsor: Amgen
Active, not recruiting --> Completed
- | oprozomib (ONX 0912) / Amgen
Enrollment change: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jul 12, 2019
P1b/2, N=210, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed N=364 --> 210
- | oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date, Combination therapy: INTREPID-1: Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 11, 2019
P1b, N=64, Recruiting, Sponsor: Amgen
N=364 --> 210 Trial completion date: Apr 2020 --> Sep 2019 | Trial primary completion date: Apr 2020 --> Sep 2019
- ||| oprozomib (ONX 0912) / Amgen
Trial completion, Enrollment change: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 28, 2019
P1b/2, N=65, Completed, Sponsor: Amgen
Trial completion date: Apr 2020 --> Sep 2019 | Trial primary completion date: Apr 2020 --> Sep 2019 Active, not recruiting --> Completed | N=128 --> 65
- | oprozomib (ONX 0912) / Amgen
Preclinical, Journal: Electrochemical assay for 20S proteasome activity and inhibition with anti-cancer drugs. (Pubmed Central) - Jun 3, 2019
Electrochemical quartz crystal microbalance and atomic force microscopy were also used to investigate substrate interaction with the 20S proteasome and their adsorption at the electrode surface. Finally, the new electrochemical assay allowed to investigate the mechanisms of two different proteasome inhibitor drugs, bortezomib and oprozomib, underlying the applicability of the assay for understanding proteasome inhibitor action.
- || oprozomib (ONX 0912) / Amgen
Trial completion: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - May 6, 2019
P1b, N=33, Completed, Sponsor: Amgen
Finally, the new electrochemical assay allowed to investigate the mechanisms of two different proteasome inhibitor drugs, bortezomib and oprozomib, underlying the applicability of the assay for understanding proteasome inhibitor action. Active, not recruiting --> Completed
- | oprozomib (ONX 0912) / Amgen
Trial completion date, Metastases: A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies (clinicaltrials.gov) - Feb 16, 2019
P1, N=45, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial completion date: Feb 2019 --> Jun 2019
- || oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 12, 2019
P1b/2, N=364, Active, not recruiting, Sponsor: Amgen
Trial completion date: Feb 2019 --> Jun 2019 Trial completion date: Feb 2019 --> Jun 2019 | Trial primary completion date: Feb 2019 --> Jun 2019
- || oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date, Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2019
P1b/2, N=134, Active, not recruiting, Sponsor: Amgen
Trial completion date: Feb 2019 --> Jun 2019 | Trial primary completion date: Feb 2019 --> Jun 2019 Trial completion date: Feb 2019 --> Jul 2019 | Trial primary completion date: Feb 2019 --> Jul 2019
- || oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2019
P1b/2, N=128, Active, not recruiting, Sponsor: Amgen
Trial completion date: Feb 2019 --> Jul 2019 | Trial primary completion date: Feb 2019 --> Jul 2019 Trial completion date: Feb 2019 --> Jun 2019 | Trial primary completion date: Feb 2019 --> Jun 2019
- || oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date, Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Sep 26, 2018
P1b/2, N=134, Active, not recruiting, Sponsor: Amgen
Trial completion date: Feb 2019 --> Jun 2019 | Trial primary completion date: Feb 2019 --> Jun 2019 Trial completion date: Sep 2018 --> Feb 2019 | Trial primary completion date: Sep 2018 --> Feb 2019
- || oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Sep 26, 2018
P1b/2, N=364, Active, not recruiting, Sponsor: Amgen
Trial completion date: Sep 2018 --> Feb 2019 | Trial primary completion date: Sep 2018 --> Feb 2019 Trial completion date: Nov 2018 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019
- | oprozomib (ONX 0912) / Amgen
Trial primary completion date: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 26, 2018
P1b, N=33, Active, not recruiting, Sponsor: Amgen
Trial completion date: Nov 2018 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019 Trial primary completion date: Oct 2018 --> Feb 2019
- | oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date, Metastases: A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 26, 2018
P1, N=45, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Oct 2018 --> Feb 2019 Trial completion date: Oct 2018 --> Feb 2019 | Trial primary completion date: May 2015 --> May 2016
- | oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 23, 2018
P1b, N=33, Active, not recruiting, Sponsor: Amgen
Trial completion date: Oct 2018 --> Feb 2019 | Trial primary completion date: May 2015 --> May 2016 Trial completion date: Jul 2018 --> Jan 2019 | Trial primary completion date: Jul 2018 --> Oct 2018
- | oprozomib (ONX 0912) / Amgen
Trial completion date, Metastases: A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies (clinicaltrials.gov) - Jul 23, 2018
P1, N=45, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jul 2018 --> Jan 2019 | Trial primary completion date: Jul 2018 --> Oct 2018 Trial completion date: Jul 2018 --> Oct 2018
- || oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date, Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jun 20, 2018
P1b/2, N=134, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jul 2018 --> Oct 2018 Trial completion date: Jun 2018 --> Sep 2018 | Trial primary completion date: Jun 2018 --> Sep 2018
- || oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 20, 2018
P1b/2, N=128, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jun 2018 --> Sep 2018 | Trial primary completion date: Jun 2018 --> Sep 2018 Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018
- || oprozomib (ONX 0912) / Amgen
Trial completion date, Trial primary completion date: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 1, 2018
P1b/2, N=364, Active, not recruiting, Sponsor: Amgen
Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018 Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: May 2018 --> Nov 2018
- || oprozomib (ONX 0912) / Amgen
Trial primary completion date, Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - May 1, 2018
P1b/2, N=134, Active, not recruiting, Sponsor: Amgen
Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: May 2018 --> Nov 2018 Trial primary completion date: Mar 2018 --> Jun 2018
- oprozomib (ONX 0912) / Amgen
Trial primary completion date: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 25, 2018
P1b, N=33, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2018 --> Jun 2018 Trial primary completion date: Apr 2018 --> Jul 2018
- oprozomib (ONX 0912) / Amgen
Trial completion date, Metastases: A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 24, 2018
P1, N=45, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Apr 2018 --> Jul 2018 Trial completion date: Apr 2018 --> Jul 2018
- oprozomib (ONX 0912) / Amgen
Enrollment closed: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 19, 2017
P1b, N=33, Active, not recruiting, Sponsor: Amgen
Trial completion date: Apr 2018 --> Jul 2018 Recruiting --> Active, not recruiting
- || oprozomib (ONX 0912) / Amgen
Trial primary completion date: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 18, 2017
P1b/2, N=128, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2017 --> Jun 2018
- || oprozomib (ONX 0912) / Amgen
Trial primary completion date: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Dec 18, 2017
P1b/2, N=364, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Nov 2017 --> May 2018
- oprozomib (ONX 0912) / Amgen
Trial primary completion date: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 18, 2017
P1b, N=33, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Nov 2017 --> May 2018 Trial primary completion date: Jan 2018 --> Apr 2018
- || oprozomib (ONX 0912) / Amgen
Trial primary completion date, Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Dec 18, 2017
P1b/2, N=134, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2018 --> Apr 2018 Trial primary completion date: Dec 2017 --> Mar 2018
- oprozomib (ONX 0912) / Amgen
Clinical: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 21, 2017
P1b, N=33, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Sep 2017 --> Jan 2018
- || oprozomib (ONX 0912) / Amgen
Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Sep 28, 2017
P1b/2, N=134, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Sep 2017 --> Jan 2018 Trial primary completion date: Aug 2017 --> Dec 2017
- || oprozomib (ONX 0912) / Amgen
Clinical: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jul 18, 2017
P1b/2, N=364, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: May 2017 --> Nov 2017
- || oprozomib (ONX 0912) / Amgen
Clinical: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 18, 2017
P1b/2, N=128, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: May 2017 --> Nov 2017 Trial primary completion date: Jul 2017 --> Dec 2017
- || oprozomib (ONX 0912) / Amgen
Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jun 21, 2017
P1b/2, N=134, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jul 2017 --> Dec 2017 Trial primary completion date: May 2017 --> Aug 2017
- oprozomib (ONX 0912) / Amgen
Enrollment change: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 21, 2017
P1b, N=33, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: May 2017 --> Aug 2017 N=314 --> 33 | Trial primary completion date: Jul 2017 --> Sep 2017 | N=314 --> 33
- oprozomib (ONX 0912) / Amgen
Phase classification: A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - May 2, 2017
P1b/2, N=9, Completed, Sponsor: Amgen
N=314 --> 33 | Trial primary completion date: Jul 2017 --> Sep 2017 | N=314 --> 33 Phase classification: P1/2 --> P1b/2
- oprozomib (ONX 0912) / Amgen
Phase classification, Combination therapy, Metastases: Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - May 2, 2017
P1b/2, N=0, Withdrawn, Sponsor: Amgen
Phase classification: P1/2 --> P1b/2 Phase classification: P1/2 --> P1b/2
- | oprozomib (ONX 0912) / Amgen, pomalidomide / Generic mfg.
Review, Journal: Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). (Pubmed Central) - Mar 14, 2017
Oprozomib (OPZ or ONYX 0912) is an irreversible, orally administered proteasome inhibitor (PI) and an analog of carfilzomib...These studies show that OPZ has anti-angiogenic effects, and that the combination of OPZ, Dex and Pom produces greater anti-MM effects in vivo when compared to any of the doublet combinations. These studies provide further support for clinical trials evaluating OPZ in combination with Pom and Dex.
- || oprozomib (ONX 0912) / Amgen
Clinical: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 14, 2017
P1b, N=314, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
These studies provide further support for clinical trials evaluating OPZ in combination with Pom and Dex. Trial primary completion date: Apr 2017 --> Jul 2017
- ||| oprozomib (ONX 0912) / Amgen
Combination therapy: INTREPID-1: Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 15, 2017
P1b, N=64, Recruiting, Sponsor: Amgen
Trial primary completion date: Apr 2017 --> Jul 2017 Not yet recruiting --> Recruiting | N=38 --> 64
- || oprozomib (ONX 0912) / Amgen
Clinical: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 2, 2017
P1b/2, N=364, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Not yet recruiting --> Recruiting | N=38 --> 64 Trial primary completion date: Nov 2016 --> May 2017
- || oprozomib (ONX 0912) / Amgen
Clinical: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 24, 2017
P1b, N=314, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Trial primary completion date: Nov 2016 --> May 2017 Trial primary completion date: Jan 2017 --> Apr 2017
- || oprozomib (ONX 0912) / Amgen
Clinical: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 24, 2017
P1b/2, N=128, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Trial primary completion date: Jan 2017 --> Apr 2017 Trial primary completion date: Jan 2017 --> Jul 2017
- | oprozomib (ONX 0912) / Amgen
Combination therapy: INTREPID-1: Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 18, 2016
P1b, N=38, Not yet recruiting, Sponsor: Amgen
- || oprozomib (ONX 0912) / Amgen
Combination therapy: Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Sep 28, 2016
P1b/2, N=134, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Trial primary completion date: Jan 2017 --> Jul 2017 Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Aug 2016 --> Feb 2017
- || oprozomib (ONX 0912) / Amgen
Clinical: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 28, 2016
P1b/2, N=128, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Aug 2016 --> Feb 2017 Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Jul 2016 --> Jan 2017
- | oprozomib (ONX 0912) / Amgen
Clinical: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Sep 28, 2016
P1b/2, N=364, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Phase classification: P1/2 --> P1b/2 | Trial primary completion date: Jul 2016 --> Jan 2017 Phase classification: P1/2 --> P1b/2
- || oprozomib (ONX 0912) / Amgen
Clinical: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 29, 2016
P1b, N=314, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Phase classification: P1/2 --> P1b/2 Phase classification: P1/2 --> P1b | Trial primary completion date: Jul 2016 --> Jan 2017
- || oprozomib (ONX 0912) / Amgen
Clinical: A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 25, 2016
P1/2, N=314, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Phase classification: P1/2 --> P1b | Trial primary completion date: Jul 2016 --> Jan 2017 Trial primary completion date: Apr 2016 --> Jul 2016
- || oprozomib (ONX 0912) / Amgen
Clinical: Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (clinicaltrials.gov) - Dec 5, 2015
P1/2, N=364, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Trial primary completion date: Apr 2016 --> Jul 2016 Trial primary completion date: May 2016 --> Sep 2016
- oprozomib (ONX 0912) / Amgen
Metastases: A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies (clinicaltrials.gov) - Nov 6, 2015
P1, N=48, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Dec 2015 --> May 2015